October 2021 Content Release Copied
Clinical Profile Documentation
The following items are available for documentation in Problems and appear on the Charge Capture Report (CCR). Additional ICD10 codes may display to present the surrounding nodes.
| Problem | ICD10 Code* |
| Abnormality of plasma protein | R77.9 – Abnormality of plasma protein, unspecified |
| Anemia co-occurrent and due to chronic kidney disease (disorder) | D63.1 – Anemia in chronic kidney disease |
| Chronic kidney disease stage 3A (GFR 45-59) | N18.31 – Chronic kidney disease, stage 3a |
| Chronic kidney disease stage 3B (GFR 30-44) | N18.32 – Chronic kidney disease, stage 3b |
| High blood pressure | I10 – Essential (primary) hypertension |
| Personal history of testicular cancer | Z85.47 – Personal history of malignant neoplasm of testis |
Lab Analyte & Panels: Additions and Updates
- A. calco-baum, qual
- Adenovirus
- B. pertussis IgG, IU/mL
- Beta HCG quant CSF panel
- BioFire comment
- BioFire pneumonia (PN) panel
- C. pneumoniae, qual
- c.1286A>C mutation
- c.665C>T mutation
- Coronavirus, qual
- CTX-M
- D-Lactate panel, plasma
- D-lactate, plasma
- E. cloacae cmp, qual
- E. coli, qual
- Flu + SARS Ag
- Flu + SARS Ag panel
- H. influenzae, qual
- HCG, beta, CSF
- IGFBP5
- IMP, qual
- Influenza A qual
- Influenza B qual
- K. aerogenes, qual
- K. oxytoca, qual
- K. pneumoni gp, qual
- KPC, qual
- L. pneumophila, qual
- Lymph appearance, manual diff
- M. pneumoniae, qual
- M.catarrhalis, qual
- mecA/C MREJ, qual
- Metapneunovir, qual
- Methylenetetrahydrofolate reductase (MTHFR), DNA panel
- MPN JAK2 V617F w/ sequential reflex to JAK2 exon 12-13, CA
- NDM, qual
- Nickel, serum/plasma
- Nickel, serum/plasma panel
- Oxa48
- P. aeruginosa, qual
- Parainfluenza virus, qual
- Progressive sperm motility
- Proteus spp, qual
- Respiratory syncytial virus, qual
- Rhino/Entero
- S. agalactiae, qual
- S. aureus, qual
- S. marcescens, qual
- S. pneumoniae, qual
- S. pyogenes, qual
- Semen analysis panel
- Semen coagulation
- Semen collection site
- Semen liquefication
- Sperm abnormal forms, %
- Sperm normal forms, %
- Total sperm count, sperm/mL
- Uric acid 24hr, gm/24hr
- Urine amy/crea clearance
- VIM
- WBC semen, qual
Diagnostic Imaging and Other Services
| Procedure | Billing Code |
| Colposcopy with biopsy of endometrium | 58110 |
| Endometrial biopsy in conjunction w/ colposcopy | 58110 |
| Endometrial biopsy w/wo endocervical biopsy, w/o cervical dilation, any method (separate procedure) | 58100 |
| Juvederm procedure | J3JUV |
| Liposonix procedure | SONIX |
| No charge nurse visit | NO CHARGE |
Medications
Additions
- AZD9833 invest Oral
- COM701 invest IV
- ELU001 invest IV
- IGM-8444 invest IV
- Immun glob G(IgG)-Malt-IgA 50+ (PF) IV 10 %
- Immun glob G(IgG)-Malt-IgA 50+ (PF) IV 5 %
- MK-3475 invest Subcutaneous
- NovoTTF-200T system
- NUV-422 invest Oral
- Octagam (PF) (Immun glob G(IgG)-Malt-IgA 50+ (PF) IV 10%)
- Octagam (PF) (Immun glob G(IgG)-Malt-IgA 50+ (PF) IV 5%)
- PF-06939999 invest Oral
- SM08502 invest Oral
- Tisotumab Vedotin-tftv IV
- Tranexamic Acid Oral Rinse
- TST005 invest IV
- ZN-c3 invest Oral
Updates
| Drug Name | Updates |
| Onasemnogene Abeparvovec-xioi IV | Added sigs:
5.5 mL intravenously Piggyback once; administer over 60 mins 8.3 mL intravenously Piggyback once; administer over 60 mins |
| Orgovyx (Relugolix Oral) | Added sig: 120 mg orally daily; Take 360 mg on day 1, then 120 mg every day |
| Wixela (Fluticasone-Salmeterol Inhaler 100 mcg-50 mcg/Dose) | Added brand: Wixela |
| Wixela (Fluticasone-Salmeterol Inhaler 250 mcg-50 mcg/Dose) | Added brand: Wixela |
| Wixela (Fluticasone-Salmeterol Inhaler 500 mcg-50 mcg/Dose) | Added brand: Wixela |
Regimens
This section does not include clinical trial regimens.
To improve efficiency and reduce infusion chair time, CCC recently voted to add and pre-check oral dexamethasone pre-medication for Daratumumab SQ as an outpatient prescription for patient self- administration.
To reduce the number of prescriptions and improve ease of use, CCC also voted to merge oral dexamethasone post-medication for Daratumumab SQ prescriptions for similar cycles.
Additions
- Mobocertinib Q30D
- Atezolizumab Q21D (Adjuvant NSCLC)
- Neratinib Dose Titration Q30D
- Pembrolizumab + Doxorubicin + Cyclophosphamide (AC) Q21D fb Pembrolizumab + Paclitaxel D1,8,15 + Carboplatin Q21D
- Stanford V Q28D
- Tisotumab vedotin-tftv Q21D
Updates
Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.
- All Problems
- Amyloidosis
- Autoimmune disease
- Colon Cancer
- Hemolytic anemia
- Liver Cancer
- Lung Cancer, Small cell (SCLC)
- Lymphoma, Hodgkin’s
- Lymphoma, Non-Hodgkin (NHL)
- Melanoma, Skin
- Multiple myeloma (MM)
- Neuroendocrine carcinoma
- Rectal Cancer
- Renal cell cancer
- Thyroid Cancer
- Waldenstrom’s macroglobulinemia
Renames
| Previous Name | New Name |
| Cabozantinib Q30D (RCC, Hepatocellular Carcinoma) | Cabozantinib (Cabometyx) Q30D (RCC, HCC, Differentiated Thyroid) |
| Cyclophosphamide PO D1,8,15 + Lenalidomide D1-21 + Dexamethasone D1,8,15,22 Q28D (Amyloidosis) | Cyclophosphamide PO D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D (Amyloidosis) |
| Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone D1,8,15,22 Q28D | Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D |
| Ixazomib D1,8,15 + Pomalidomide D1-21 + Dexamethasone D1,8,15,22 Q28D | Ixazomib D1,8,15 + Pomalidomide D1-21 + Dexamethasone Q28D |
| Nivolumab + Ipilimumab Q21D (Renal Cell Carcinoma, Colon, Rectal) | Nivolumab + Ipilimumab Q21D (RCC, Colon, Rectal, Neuroendocrine) |
Research Regimens
Additions
To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.
Updates
| Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes | |
| USOR 17160 | X | X | X | |
| USOR 19088 | X | |||
| USOR 19109 | X | X | X | Now available for ordering:
|
| USOR 19156 | No longer available for ordering:
|
|||
| USOR 19221 | X | X | X | |
| 20133 | X | X | ||
| USOR 20176 | X | X | X | Now available for ordering: USOR 20176 Group E Epacadostat (PO; BID) + INCMGA00012 Q28D |
| USOR 20223 | X | |||
| USOR 20287 | X | X | ||
| USOR 20297 | X | X | X | Now available for ordering: USOR 20297 BDC-1001 Monotherapy Q14D
No longer available for ordering: USOR 20297 BDC-1001 + Pembrolizumab Q21D |
| USOR 20298 | X | X | ||
| USOR 20331 | X | X | ||
| USOR 20352 | X | X | ||
| USOR 20413 | X | X | X | |
| USOR 21304 | X | X | X | Now available for ordering:
|
| USOR 21304 (continued) | X | X | X | No longer available for ordering:
|
Billing: HCPCS Code Updates
| Medication | HCPCS Code |
| COVID-19 Vac,Tris (Pfizer) (PF) IM (5 yrs thru 11 yrs) (Unapproved) | 91307 per 0.2 mL |
| COVID-19 Vac,Tris (Pfizer) (PF) IM (12 yrs & older) (Unapproved) | 91305 per 0.3 mL |
| Dengue Vaccine, Live, Vero (PF) Subcutaneous | 90587 per 0.5 mL |
| Immun glob G(igG)-Malt-IgA 50+ (PF) IV 5 % | J1568 per 500 mg J1568 per 0.5 g |
| Immun glob G(igG)-Malt-IgA 50+ (PF) IV 10 % | J1568 per 0.5 g |
| Insulin Glargine-yfgn Subcutaneous 100 unit/mL | J1815 per 5 UNITS |
| Onasemnogene Abeparvovec-xioi IV | J3399 per 5.5 mL J3399 per 8.3 mL |
| Tisotumab vedotin-tftv IV | J3590 per 40 mg |